Elicera Therapeutics AB
Clinical-stage immuno-oncology company developing cell and gene therapies for cancer.
ELIC | ST
Overview
Corporate Details
- ISIN(s):
- SE0015382080 (+1 more)
- LEI:
- 549300I35L0R4INBFG27
- Country:
- Sweden
- Address:
- C/O Elicera Therapeutics AB, 402 24 Göteborg
- Website:
- https://elicera.com/
Description
Elicera Therapeutics AB is a clinical-stage immuno-oncology company developing cell and gene therapies for cancer treatment. The company's portfolio is based on two main approaches: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. A central component of its technology is the proprietary iTANK (Immuno-Oncology Targeting and Killing) platform. The iTANK platform is designed to enhance the efficacy of CAR T-cell therapies by arming them to activate a patient's own immune system, creating a broad, multi-targeted attack against cancer cells. This mechanism aims to address challenges such as tumor antigen heterogeneity, particularly in solid tumors. The company's pipeline includes several drug candidates in clinical development for indications including neuroendocrine tumors and B-cell lymphoma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Elicera Therapeutics AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-11 | Margareth Jorvid | Other | Other | 21,700 | 40,145.00 SEK |
Peer Companies
